ASX:MSBBiotechs
Mesoblast (ASX:MSB) Is Up 6.1% After FDA Clears Registrational DMD Trial for Ryoncil
On 8 April 2026, Mesoblast Limited announced that the FDA granted Investigational New Drug clearance to proceed directly to a registrational trial of Ryoncil (remestemcel‑L‑rknd) in 76 children with Duchenne muscular dystrophy, using time‑to‑stand at nine months as the primary endpoint.
This marks an expansion of Ryoncil’s use beyond steroid‑refractory acute graft‑versus‑host disease into another rare pediatric indication, leveraging its existing FDA‑approved manufacturing platform and...